|
1
|
Watanabe T, Muro K, Ajioka Y, Hashiguchi
Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S,
et al Japanese Society for Cancer of the Colon and Rectum: Japanese
Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016
for the treatment of colorectal cancer. Int J Clin Oncol. Mar
27–2017.Epub ahead of print. View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Steele SR, Chang GJ, Hendren S, Weiser M,
Irani J, Buie WD and Rafferty JF; Clinical Practice Guidelines
Committee of the American Society of Colon and Rectal Surgeons:
Practice guideline for the surveillance of patients after curative
treatment of colon and rectal cancer. Dis Colon Rectum. 58:713–725.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vermeulen L, de Sousa e Melo F, Richel DJ
and Medema JP: The developing cancer stem-cell model: Clinical
challenges and opportunities. Lancet Oncol. 13:e83–e89. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells - perspectives on current status and future directions:
AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kishikawa J, Kazama S, Oba K, Hasegawa K,
Anzai H, Harada Y, Abe H, Matsusaka K, Hongo K, Oba M, et al: CD133
Expression at the metastatic site predicts patients’ outcome in
colorectal cancer with synchronous liver metastasis. Ann Surg
Oncol. 23:1916–1923. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamamoto S, Tanaka K, Takeda K, Akiyama H,
Ichikawa Y, Nagashima Y and Endo I: Patients with CD133-negative
colorectal liver metastasis have a poor prognosis after
hepatectomy. Ann Surg Oncol. 21:1853–1861. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pitule P, Cedikova M, Daum O, Vojtisek J,
Vycital O, Hosek P, Treska V, Hes O, Kralickova M and Liska V:
Immunohistochemical detection of cancer stem cell related markers
CD44 and CD133 in metastatic colorectal cancer patients. BioMed Res
Int. 2014:4321392014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours. 7th. Wiley-Blackwell;
West Sussex: 2010
|
|
11
|
Maeda S, Shinchi H, Kurahara H, Mataki Y,
Maemura K, Sato M, Natsugoe S, Aikou T and Takao S: CD133
expression is correlated with lymph node metastasis and vascular
endothelial growth factor-C expression in pancreatic cancer. Br J
Cancer. 98:1389–1397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saigusa S, Inoue Y, Tanaka K, Toiyama Y,
Matsushita K, Kawamura M, Okugawa Y, Hiro J, Uchida K, Mohri Y, et
al: Clinical significance of LGR5 and CD44 expression in locally
advanced rectal cancer after preoperative chemoradiotherapy. Int J
Oncol. 41:1643–1652. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Collett D: Modelling Survival Data in
Medical Research. 3rd. CRC Press; London: 2015
|
|
14
|
Chen S, Song X, Chen Z, Li X, Li M, Liu H
and Li J: CD133 expression and the prognosis of colorectal cancer:
A systematic review and meta-analysis. PLoS One. 8:e563802013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Y, Peng J, Zhang E, Jiang N, Li J,
Zhang Q, Zhang X and Niu Y: CD133 expression may be useful as a
prognostic indicator in colorectal cancer, a tool for optimizing
therapy and supportive evidence for the cancer stem cell
hypothesis: A meta-analysis. Oncotarget. 7:10023–10036.
2016.PubMed/NCBI
|
|
16
|
Horst D, Scheel SK, Liebmann S, Neumann J,
Maatz S, Kirchner T and Jung A: The cancer stem cell marker CD133
has high prognostic impact but unknown functional relevance for the
metastasis of human colon cancer. J Pathol. 219:427–434. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kemper K, Versloot M, Cameron K, Colak S,
de Sousa e Melo F, de Jong JH, Bleackley J, Vermeulen L, Versteeg
R, Koster J, et al: Mutations in the Ras-Raf Axis underlie the
prognostic value of CD133 in colorectal cancer. Clin Cancer Res.
18:3132–3141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shmelkov SV, Butler JM, Hooper AT, Hormigo
A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, et
al: CD133 expression is not restricted to stem cells, and both
CD133+ and CD133− metastatic colon cancer
cells initiate tumors. J Clin Invest. 118:2111–2120.
2008.PubMed/NCBI
|
|
19
|
Hongo K, Tanaka J, Tsuno NH, Kawai K,
Nishikawa T, Shuno Y, Sasaki K, Kaneko M, Hiyoshi M, Sunami E, et
al: CD133(−) cells, derived from a single human colon cancer cell
line, are more resistant to 5-fluorouracil (FU) than CD133(+)
cells, dependent on the β1-integrin signaling. J Surg Res.
175:278–288. 2012. View Article : Google Scholar
|
|
20
|
Horst D, Kriegl L, Engel J, Kirchner T and
Jung A: CD133 expression is an independent prognostic marker for
low survival in colorectal cancer. Br J Cancer. 99:1285–1289. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ueno H, Murphy J, Jass JR, Mochizuki H and
Talbot IC: Tumour ‘budding’ as an index to estimate the potential
of aggressiveness in rectal cancer. Histopathology. 40:127–132.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ong CW, Kim LG, Kong HH, Low LY, Iacopetta
B, Soong R and Salto-Tellez M: CD133 expression predicts for
non-response to chemotherapy in colorectal cancer. Mod Pathol.
23:450–457. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stanisavljević L, Myklebust MP, Leh S and
Dahl O: LGR5 and CD133 as prognostic and predictive markers for
fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Acta Oncol. 55:1425–1433. 2016. View Article : Google Scholar
|
|
24
|
Sluiter N, de Cuba E, Kwakman R, Kazemier
G, Meijer G and Te Velde EA: Adhesion molecules in peritoneal
dissemination: Function, prognostic relevance and therapeutic
options. Clin Exp Metastasis. 33:401–416. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen J, Xia Q, Jiang B, Chang W, Yuan W,
Ma Z, Liu Z and Shu X: Prognostic value of cancer stem cell marker
ALDH1 expression in colorectal cancer: A systematic review and
meta-analysis. PLoS One. 10:e01451642015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Verwaal VJ, van Ruth S, Witkamp A, Boot H,
van Slooten G and Zoetmulder FA: Long-term survival of peritoneal
carcinomatosis of colorectal origin. Ann Surg Oncol. 12:65–71.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nagata H, Ishihara S, Hata K, Murono K,
Kaneko M, Yasuda K, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, et
al: Survival and prognostic factors for metachronous peritoneal
metastasis in patients with colon cancer. Ann Surg Oncol.
24:1269–1280. 2017. View Article : Google Scholar
|
